The figure represents the frequency ofAblkinase domain mutations detected in clinical specimens from 245 patients with mutations (219 with CML and 26 with Ph+ acute lymphoblastic leukemia). The numbering on the X-axis represents the amino acid location and the letters inside the circles indicate the amino acid encoded by the mutated nucleotide. On the Y-axis, the percentage of patients with each mutation is color-coded as shown in the box. The data is derived from 20 published papers as detailed in the primary manuscript.9 This research was originally published in Blood. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37. © the American Society of Hematology.
